BR112016013516A8 - complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula - Google Patents
complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula Download PDFInfo
- Publication number
- BR112016013516A8 BR112016013516A8 BR112016013516A BR112016013516A BR112016013516A8 BR 112016013516 A8 BR112016013516 A8 BR 112016013516A8 BR 112016013516 A BR112016013516 A BR 112016013516A BR 112016013516 A BR112016013516 A BR 112016013516A BR 112016013516 A8 BR112016013516 A8 BR 112016013516A8
- Authority
- BR
- Brazil
- Prior art keywords
- cell
- charge
- peptides
- cells
- polyanion
- Prior art date
Links
- 238000001890 transfection Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000001415 gene therapy Methods 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 229920000447 polyanionic polymer Polymers 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- -1 cationic lipid Chemical class 0.000 abstract 1
- 210000004748 cultured cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915429P | 2013-12-12 | 2013-12-12 | |
| PCT/US2014/070176 WO2015089487A1 (en) | 2013-12-12 | 2014-12-12 | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016013516A2 BR112016013516A2 (https=) | 2017-08-08 |
| BR112016013516A8 true BR112016013516A8 (pt) | 2020-05-19 |
Family
ID=52273587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016013516A BR112016013516A8 (pt) | 2013-12-12 | 2014-12-12 | complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US9856496B2 (https=) |
| EP (2) | EP3079723B1 (https=) |
| JP (2) | JP6912887B2 (https=) |
| KR (1) | KR102532559B1 (https=) |
| CN (2) | CN106456793B (https=) |
| AU (2) | AU2014361806B2 (https=) |
| BR (1) | BR112016013516A8 (https=) |
| CA (1) | CA2933561A1 (https=) |
| ES (1) | ES2808866T3 (https=) |
| SG (2) | SG10201811729PA (https=) |
| WO (1) | WO2015089487A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013166339A1 (en) * | 2012-05-02 | 2013-11-07 | Life Technologies Corporation | High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers |
| KR101996592B1 (ko) | 2012-06-15 | 2019-07-04 | 인텔 코포레이션 | 명확화 없는 비순차 load store 큐를 갖는 재정렬된 투기적 명령어 시퀀스들 |
| WO2013188705A2 (en) | 2012-06-15 | 2013-12-19 | Soft Machines, Inc. | A virtual load store queue having a dynamic dispatch window with a unified structure |
| TWI646422B (zh) | 2012-06-15 | 2019-01-01 | 英特爾股份有限公司 | 在處理器中之免消歧義失序載入／儲存佇列方法、微處理器、和非暫態性電腦可讀取儲存媒體 |
| CN104583956B (zh) | 2012-06-15 | 2019-01-04 | 英特尔公司 | 用于实现加载存储重新排序和优化的指令定义 |
| EP2862084A4 (en) | 2012-06-15 | 2016-11-30 | Soft Machines Inc | METHOD AND SYSTEM FOR IMPLEMENTING RECOVERY FROM A SPECULATIVE TRANSMISSION OF FAULT FORECASTS / ERRORS DUE TO THE CHANGE AND OPTIMIZATION OF MEMORY LOADS |
| EP2862062B1 (en) | 2012-06-15 | 2024-03-06 | Intel Corporation | A virtual load store queue having a dynamic dispatch window with a distributed structure |
| SG10201811729PA (en) | 2013-12-12 | 2019-02-27 | Life Technologies Corp | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| JP7199809B2 (ja) | 2015-02-13 | 2023-01-06 | ファクター バイオサイエンス インコーポレイテッド | 核酸製品及びその投与方法 |
| EP3322813A1 (en) | 2015-07-13 | 2018-05-23 | Life Technologies Corporation | System and method for improved transient protein expression in cho cells |
| CN108779074A (zh) * | 2016-03-01 | 2018-11-09 | 分子传递有限公司 | 植物病毒移动蛋白和其使用方法 |
| US10576167B2 (en) | 2016-08-17 | 2020-03-03 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| JP7216641B2 (ja) * | 2016-09-30 | 2023-02-01 | ライフ テクノロジーズ コーポレイション | レンチウイルス製造用無血清懸濁系 |
| EP3675826B1 (en) | 2017-08-31 | 2023-05-31 | Life Technologies Corporation | Cationic lipid compositions for tissue-specific delivery |
| CA3076199A1 (en) | 2017-09-19 | 2019-03-28 | Cannametrix, Llc | Cell-based assay for quantifying the potency and efficacy of cannabinoids and/or terpenoids, and methods of use thereof |
| MA52148A (fr) * | 2018-03-16 | 2021-01-20 | Sarepta Therapeutics Inc | Peptides chimères pour administration d'antisens |
| US20210388393A1 (en) * | 2018-10-12 | 2021-12-16 | Ann & Robert H. Lurie Children's Hospital of Chicago | Plga-peg/pei nanoparticles and methods of use |
| GB201821269D0 (en) | 2018-12-28 | 2019-02-13 | Nippon Shinyaku Co Ltd | Myostatin signal inhibitor |
| AU2020225632A1 (en) | 2019-02-22 | 2021-09-02 | Life Technologies Corporation | Suspension system for adeno associated virus production |
| KR102261371B1 (ko) * | 2019-04-01 | 2021-06-08 | 한양대학교 산학협력단 | CP2c 표적 펩티드 기반 항암제 |
| CN113874029B (zh) | 2019-04-01 | 2025-02-11 | 汉阳大学校产学协力团 | 基于cp2c靶向肽的抗癌剂 |
| BR112022002143A2 (pt) * | 2019-08-05 | 2022-04-19 | Polyplus Transfection | Composição adequada para transfectar uma molécula de ácido nucleico em uma célula, métodos para transfecção in vitro ou ex vivo de células vivas e para a produção e usos in vitro ou ex vivo da composição |
| KR102515464B1 (ko) * | 2020-04-29 | 2023-03-28 | 연세대학교 원주산학협력단 | 핵산 또는 유전자 형질감염 효율을 개선하는 세포독성 완화 막 투과 펩타이드 및 이의 용도 |
| US20260027179A1 (en) * | 2021-02-08 | 2026-01-29 | University Of British Columbia | Anti-synucleinopathy peptide and methods to treat neurodegenerative diseases |
| US20240285547A1 (en) | 2021-07-08 | 2024-08-29 | Nippon Shinyaku Co., Ltd. | Nephrotoxicity reducing agent |
| US20240285770A1 (en) | 2021-07-08 | 2024-08-29 | Nippon Shinyaku Co., Ltd. | Precipitation suppressing agent |
| CN118475355A (zh) | 2021-07-08 | 2024-08-09 | 日本新药株式会社 | 肾毒性减轻剂 |
| CN113563429A (zh) * | 2021-07-19 | 2021-10-29 | 天津大学 | 一种基于烷基化多肽的核酸递送系统及制备方法与应用 |
| WO2023014909A1 (en) * | 2021-08-04 | 2023-02-09 | AJK Biopharmaceutical, LLC | Amphiphilic peptides for nucleic acid and protein delivery |
| CN114106095B (zh) * | 2021-11-11 | 2023-06-09 | 华南理工大学 | 基于聚集诱导发光原理的细胞自噬检测分子探针及其制备方法和应用 |
| CN120129745A (zh) | 2022-03-10 | 2025-06-10 | 日本新药株式会社 | 抗病毒反义低聚物 |
| KR102717793B1 (ko) * | 2022-05-26 | 2024-10-16 | 주식회사 바이오셀트란 | 신규한 미백 펩타이드 및 이를 함유하는 화장료 조성물 |
| WO2024006937A1 (en) | 2022-06-30 | 2024-01-04 | Life Technologies Corporation | Lipid compositions for in vivo delivery |
| GB202211597D0 (en) | 2022-08-09 | 2022-09-21 | Nchain Licensing Ag | Computer-implemented method and system |
| EP4642434A2 (en) | 2022-12-29 | 2025-11-05 | Life Technologies Corporation | Lipid compositions on the basis of ionizable lipids, use for delivery to immune cells |
| CN115947817B (zh) * | 2023-02-22 | 2024-07-02 | 甘肃中肽生物科技有限公司 | 一种肿瘤相关多肽及其制备方法和应用 |
| WO2026036019A1 (en) | 2024-08-09 | 2026-02-12 | Life Technologies Corporation | Method of producing a recombinant protein in hek-293 cells |
| WO2026076376A1 (en) | 2024-10-06 | 2026-04-09 | Mirus Bio Llc | Transfection reagent comprising cationic polymer and amphipathic compound |
| CN119775363A (zh) * | 2024-12-31 | 2025-04-08 | 澳门科技大学 | 一种多肽、免疫原、疫苗和用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| FR2645866B1 (fr) | 1989-04-17 | 1991-07-05 | Centre Nat Rech Scient | Nouvelles lipopolyamines, leur preparation et leur emploi |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5334761A (en) | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US5316948A (en) | 1992-09-04 | 1994-05-31 | Life Technologies, Inc. | N4 -methyl-2'-deoxycytidine 5'-triphosphate and its use in polymerase-catalyzed nucleic acid syntheses |
| WO1995002698A1 (en) | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| US5674908A (en) | 1993-12-20 | 1997-10-07 | Life Technologies, Inc. | Highly packed polycationic ammonium, sulfonium and phosphonium lipids |
| US6075012A (en) | 1994-02-11 | 2000-06-13 | Life Technologies, Inc. | Reagents for intracellular delivery of macromolecules |
| US5627159A (en) | 1994-10-27 | 1997-05-06 | Life Technologies, Inc. | Enhancement of lipid cationic transfections in the presence of serum |
| US6051429A (en) * | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5736392A (en) | 1995-06-07 | 1998-04-07 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| SE9804614A0 (en) | 1998-07-06 | 2000-01-07 | A+ Science Invest Ab | New peptides and use thereof |
| DK1129064T3 (da) | 1998-11-12 | 2008-04-28 | Invitrogen Corp | Transfektionsreagenser |
| US6664040B2 (en) | 2000-05-23 | 2003-12-16 | The Regents Of The University Of California | Compositions and methods for delivery of a molecule into a cell |
| EP1301213B1 (en) * | 2000-07-21 | 2017-01-18 | ReVance Therapeutics, Inc. | Multi-component biological transport systems |
| GB0103110D0 (en) | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| GB0106315D0 (en) * | 2001-03-14 | 2001-05-02 | Ich Productions Ltd | Transfection complexes |
| US20040176282A1 (en) | 2003-01-09 | 2004-09-09 | Brian Dalby | Cellular delivery and activation of polypeptide-nucleic acid complexes |
| US7531693B2 (en) | 2003-05-22 | 2009-05-12 | Molecular Transfer, Inc. | Lipids for transfection of nucleic acids |
| ES2330115T3 (es) * | 2003-08-14 | 2009-12-04 | Cellectis | Composicion antibacteriana, mas particilarmente contra las bacterias gram-negativas, que comprende un peptido y un agente antibacteriano ventajosamente hidrofobo. |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| CA2633063A1 (en) | 2005-12-16 | 2007-06-21 | Diatos | Cell penetrating peptide conjugates for delivering of nucleic acids intocells |
| PL1966240T6 (pl) * | 2005-12-30 | 2012-05-31 | Evonik Roehm Gmbh | Peptydy laktoferyny użyteczne jako peptydy penetrujące komórkę |
| KR101394768B1 (ko) | 2006-03-30 | 2014-05-21 | 드라이스 파마슈티컬스 아이엔씨 | 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물 |
| EP2604255B1 (en) | 2006-05-05 | 2017-10-25 | Molecular Transfer, Inc. | Novel reagents for transfection of eukaryotic cells |
| WO2008108505A1 (ja) | 2007-03-07 | 2008-09-12 | Japan As Represented By President Of International Medical Center Of Japan | 新規核内移行ペプチド |
| JP2012513218A (ja) | 2008-12-23 | 2012-06-14 | ヴィヴォスクリプト，インコーポレイテッド | 遺伝子改変を伴わずに細胞を再プログラミングするための組成物および方法 |
| US20110053829A1 (en) * | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
| WO2011127210A1 (en) | 2010-04-06 | 2011-10-13 | Massachusetts Institute Of Technology | Targeted delivery of nucleic acids |
| CN103097397B (zh) * | 2010-05-30 | 2015-11-25 | 多伦多大学管理委员会 | 作为抗癌化合物载体的线粒体穿透肽 |
| EP2579899B1 (en) | 2010-06-14 | 2017-03-15 | F. Hoffmann-La Roche AG | Cell-penetrating peptides and uses thereof |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US20120136073A1 (en) | 2010-11-15 | 2012-05-31 | Life Technologies Corporation | Amine-Containing Transfection Reagents and methods for making and using same |
| CN102153629B (zh) * | 2011-01-20 | 2013-07-24 | 华中科技大学 | 一种短肽及其应用 |
| US8853145B2 (en) * | 2011-11-14 | 2014-10-07 | Carlos Witte-Hoffmann | BLID; a novel protein domain for interaction with the Bcl-2 family of proteins |
| AU2013231851A1 (en) | 2012-03-15 | 2014-09-11 | Permeon Biologics, Inc. | Cell penetrating compositions for delivery of intracellular antibodies and antibody-like moieties and methods of use |
| SG10201811729PA (en) | 2013-12-12 | 2019-02-27 | Life Technologies Corp | Membrane-penetrating peptides to enhance transfection and compositions and methods for using same |
| KR102476764B1 (ko) * | 2015-12-23 | 2022-12-14 | 에스케이하이닉스 주식회사 | 소자분리구조 및 그 제조 방법 |
| US9926825B2 (en) | 2016-04-19 | 2018-03-27 | GM Global Technology Operations LLC | Method and apparatus for exhaust purification for an internal combustion engine |
-
2014
- 2014-12-12 SG SG10201811729PA patent/SG10201811729PA/en unknown
- 2014-12-12 EP EP14821440.6A patent/EP3079723B1/en active Active
- 2014-12-12 CN CN201480074785.5A patent/CN106456793B/zh active Active
- 2014-12-12 EP EP20176262.2A patent/EP3756690A3/en active Pending
- 2014-12-12 SG SG11201604697TA patent/SG11201604697TA/en unknown
- 2014-12-12 ES ES14821440T patent/ES2808866T3/es active Active
- 2014-12-12 CA CA2933561A patent/CA2933561A1/en active Pending
- 2014-12-12 AU AU2014361806A patent/AU2014361806B2/en active Active
- 2014-12-12 CN CN202110386654.2A patent/CN113105559A/zh active Pending
- 2014-12-12 JP JP2016538724A patent/JP6912887B2/ja active Active
- 2014-12-12 BR BR112016013516A patent/BR112016013516A8/pt not_active Application Discontinuation
- 2014-12-12 US US14/569,583 patent/US9856496B2/en active Active
- 2014-12-12 WO PCT/US2014/070176 patent/WO2015089487A1/en not_active Ceased
- 2014-12-12 KR KR1020167018604A patent/KR102532559B1/ko active Active
-
2017
- 2017-11-13 US US15/811,423 patent/US10760098B2/en active Active
-
2019
- 2019-09-17 JP JP2019168228A patent/JP6985347B2/ja active Active
-
2020
- 2020-03-19 AU AU2020202002A patent/AU2020202002B2/en active Active
- 2020-08-28 US US17/006,629 patent/US12152248B2/en active Active
-
2024
- 2024-10-10 US US18/911,619 patent/US20250109412A1/en active Pending
-
2025
- 2025-01-17 US US19/030,391 patent/US20250263751A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201604697TA (en) | 2016-07-28 |
| AU2014361806A1 (en) | 2016-07-28 |
| JP6985347B2 (ja) | 2021-12-22 |
| CN106456793B (zh) | 2021-04-30 |
| EP3756690A3 (en) | 2021-03-17 |
| ES2808866T3 (es) | 2021-03-02 |
| KR20160103024A (ko) | 2016-08-31 |
| US20200392537A1 (en) | 2020-12-17 |
| US20150211021A1 (en) | 2015-07-30 |
| SG10201811729PA (en) | 2019-02-27 |
| US9856496B2 (en) | 2018-01-02 |
| AU2014361806B2 (en) | 2019-12-19 |
| JP2017500856A (ja) | 2017-01-12 |
| AU2020202002B2 (en) | 2021-08-05 |
| CA2933561A1 (en) | 2015-06-18 |
| EP3756690A2 (en) | 2020-12-30 |
| EP3079723B1 (en) | 2020-05-27 |
| BR112016013516A2 (https=) | 2017-08-08 |
| KR102532559B1 (ko) | 2023-05-16 |
| JP6912887B2 (ja) | 2021-08-04 |
| AU2020202002A1 (en) | 2020-04-09 |
| US20250263751A1 (en) | 2025-08-21 |
| US12152248B2 (en) | 2024-11-26 |
| EP3079723A1 (en) | 2016-10-19 |
| US10760098B2 (en) | 2020-09-01 |
| CN113105559A (zh) | 2021-07-13 |
| WO2015089487A1 (en) | 2015-06-18 |
| US20180163231A1 (en) | 2018-06-14 |
| JP2020015747A (ja) | 2020-01-30 |
| CN106456793A (zh) | 2017-02-22 |
| US20250109412A1 (en) | 2025-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016013516A8 (pt) | complexo de transfecção e seu uso para aumentar transporte de molécula de carga em células e para o tratamento de câncer e terapia gênica, bem como método in vitro para fornecer um poliânion a uma célula | |
| JP7235702B2 (ja) | 核酸生成及び送達のための方法及び製品 | |
| Quesenberry et al. | Role of extracellular RNA-carrying vesicles in cell differentiation and reprogramming | |
| BR112013024220B8 (pt) | Métodos de introdução de um ácido nucleico de interesse em uma célula vegetal com parede celular, de expressão estável de um gene e de transferência de um gene para uma célula vegetal | |
| BR112014008932A2 (pt) | bicamadas lipídicas suportadas em nanopartículas porosas (protocélulas) para administração direcionada, incluindo a administração transdérmica de uma carga e métodos associados | |
| ES2705052T3 (es) | Micropartículas de células madre y ARNmi | |
| BR112013002298A2 (pt) | complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica. | |
| BR112012008142A8 (pt) | conjugados de peptídeo/ polietilenoglicol ligados a dissulfeto para a transfecção de ácidos nucleicos | |
| US10265347B2 (en) | Biomolecular group related to cell anti-aging | |
| Kim et al. | Stanniocalcin 2 enhances mesenchymal stem cell survival by suppressing oxidative stress | |
| BR112012022223A8 (pt) | Formulação de proteína concentrada, uso e método de preparação da mesma | |
| Zuris et al. | Efficient delivery of genome-editing proteins in vitro and in vivo | |
| WO2011150127A3 (en) | Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| WO2021113851A3 (en) | Peptide docking vehicle for targeted nucleic acid delivery | |
| Alabere et al. | Noncoding RNA as potential therapeutics to rescue mitochondrial dysfunction in cardiovascular diseases | |
| WO2014006452A3 (en) | Rapid alkalinization factor peptides for delivery of nucleic acid molecules into cells | |
| BR112014028951A8 (pt) | Peptídeos ledgf, seu uso, composição, sequência de ácido nucleico, e vetor | |
| ES2559106A1 (es) | Método de activación de la expresión del gen Pitx2 para promover la regeneración muscular | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| ES2459868B1 (es) | PROCEDIMIENTO DE OBTENCIÓN DE CÉLULAS PLURIPOTENTES INDUCIDAS (iPS), LAS CÉLULAS iPS OBTENIDAS Y USOS DE LAS MISMAS | |
| HK40100634A (en) | Methods and products for nucleic acid production and delivery | |
| MX2019013549A (es) | Peptido sintetico con actividad cariofilica para la entrega eficiente de genes mediante el nanoacarreador nts-poliplex. | |
| BR112015009804A2 (pt) | Composição que compreende uma molécula de rna sintético que codifica uma proteína de edição de genes | |
| BR132016008209F1 (pt) | Nanocomplexos para entrega de ácidos nucléicos, processo de preparação e usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |